2jde
From Proteopedia
(New page: 200px<br /><applet load="2jde" size="350" color="white" frame="true" align="right" spinBox="true" caption="2jde" /> ''''''<br /> ==About this Structure== is a [h...) |
|||
| Line 1: | Line 1: | ||
[[Image:2jde.jpg|left|200px]]<br /><applet load="2jde" size="350" color="white" frame="true" align="right" spinBox="true" | [[Image:2jde.jpg|left|200px]]<br /><applet load="2jde" size="350" color="white" frame="true" align="right" spinBox="true" | ||
| - | caption="2jde" /> | + | caption="2jde, resolution 2.20Å" /> |
| - | ''''''<br /> | + | '''UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE'''<br /> |
| + | |||
| + | ==Overview== | ||
| + | 1-isoquinolinylguanidines were previously disclosed as potent and, selective inhibitors of urokinase-type plasminogen activator (uPA)., Further investigation of this template has revealed that incorporation of, a 7-sulfonamide group furnishes a new series of potent and highly, selective uPA inhibitors. Potency and selectivity can be achieved with, sulfonamides derived from a variety of amines and is further enhanced by, the incorporation of sulfonamides derived from amino acids. The binding, mode of these 1-isoquinolinylguanidines has been investigated by X-ray, cocrystallization studies. uPA inhibitor 26 was selected for further, evaluation based on its excellent enzyme potency (Ki 10 nM) and, selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin)., In vitro, compound 26 is able to inhibit exogenous uPA in human chronic, wound fluid (IC50=0.89 microM). In vivo, in a porcine acute excisional, wound model, following topical delivery, compound 26 is able to penetrate, into pig wounds and inhibit exogenous uPA activity with no adverse effect, on wound healing parameters. On the basis of this profile, compound 26, (UK-371,804) was selected as a candidate for further preclinical, evaluation for the treatment of chronic dermal ulcers. | ||
==About this Structure== | ==About this Structure== | ||
| - | + | 2JDE is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/ ]. Active as [http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2JDE OCA]. | |
| - | [[Category: | + | |
| + | ==Reference== | ||
| + | Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines., Fish PV, Barber CG, Brown DG, Butt R, Collis MG, Dickinson RP, Henry BT, Horne VA, Huggins JP, King E, O'Gara M, McCleverty D, McIntosh F, Phillips C, Webster R, J Med Chem. 2007 May 17;50(10):2341-51. Epub 2007 Apr 21. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17447747 17447747] | ||
| + | [[Category: Single protein]] | ||
| + | [[Category: U-plasminogen activator]] | ||
| + | [[Category: Barber, C.G.]] | ||
| + | [[Category: Brown, D.G.]] | ||
| + | [[Category: Butt, R.]] | ||
| + | [[Category: Collis, M.G.]] | ||
| + | [[Category: Dickinson, R.P.]] | ||
| + | [[Category: Fish, P.V.]] | ||
| + | [[Category: Gara, M.O.]] | ||
| + | [[Category: Henry, B.T.]] | ||
| + | [[Category: Horne, V.A.]] | ||
| + | [[Category: Huggins, J.P.]] | ||
| + | [[Category: King, E.]] | ||
| + | [[Category: Mccleverty, D.]] | ||
| + | [[Category: Mcintosh, F.]] | ||
| + | [[Category: Phillips, C.]] | ||
| + | [[Category: Webster, R.]] | ||
| + | [[Category: blood coagulation]] | ||
| + | [[Category: egf-like domain]] | ||
| + | [[Category: fibrinolysis]] | ||
| + | [[Category: glycoprotein]] | ||
| + | [[Category: hydrolase]] | ||
| + | [[Category: inhibitor complex]] | ||
| + | [[Category: kringle]] | ||
| + | [[Category: pharmaceutical]] | ||
| + | [[Category: phosphorylation]] | ||
| + | [[Category: plasminogen activation]] | ||
| + | [[Category: polymorphism]] | ||
| + | [[Category: protease]] | ||
| + | [[Category: serine protease]] | ||
| + | [[Category: upa]] | ||
| + | [[Category: zymogen]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Feb 6 | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Feb 6 17:22:12 2008'' |
Revision as of 15:22, 6 February 2008
|
UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
Overview
1-isoquinolinylguanidines were previously disclosed as potent and, selective inhibitors of urokinase-type plasminogen activator (uPA)., Further investigation of this template has revealed that incorporation of, a 7-sulfonamide group furnishes a new series of potent and highly, selective uPA inhibitors. Potency and selectivity can be achieved with, sulfonamides derived from a variety of amines and is further enhanced by, the incorporation of sulfonamides derived from amino acids. The binding, mode of these 1-isoquinolinylguanidines has been investigated by X-ray, cocrystallization studies. uPA inhibitor 26 was selected for further, evaluation based on its excellent enzyme potency (Ki 10 nM) and, selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin)., In vitro, compound 26 is able to inhibit exogenous uPA in human chronic, wound fluid (IC50=0.89 microM). In vivo, in a porcine acute excisional, wound model, following topical delivery, compound 26 is able to penetrate, into pig wounds and inhibit exogenous uPA activity with no adverse effect, on wound healing parameters. On the basis of this profile, compound 26, (UK-371,804) was selected as a candidate for further preclinical, evaluation for the treatment of chronic dermal ulcers.
About this Structure
2JDE is a Single protein structure of sequence from [1]. Active as U-plasminogen activator, with EC number 3.4.21.73 Full crystallographic information is available from OCA.
Reference
Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines., Fish PV, Barber CG, Brown DG, Butt R, Collis MG, Dickinson RP, Henry BT, Horne VA, Huggins JP, King E, O'Gara M, McCleverty D, McIntosh F, Phillips C, Webster R, J Med Chem. 2007 May 17;50(10):2341-51. Epub 2007 Apr 21. PMID:17447747
Page seeded by OCA on Wed Feb 6 17:22:12 2008
Categories: Single protein | U-plasminogen activator | Barber, C.G. | Brown, D.G. | Butt, R. | Collis, M.G. | Dickinson, R.P. | Fish, P.V. | Gara, M.O. | Henry, B.T. | Horne, V.A. | Huggins, J.P. | King, E. | Mccleverty, D. | Mcintosh, F. | Phillips, C. | Webster, R. | Blood coagulation | Egf-like domain | Fibrinolysis | Glycoprotein | Hydrolase | Inhibitor complex | Kringle | Pharmaceutical | Phosphorylation | Plasminogen activation | Polymorphism | Protease | Serine protease | Upa | Zymogen
